Related Experiment Video
Updated: May 28, 2025

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet
Published on: November 4, 2015
[Chronic thromboembolic pulmonary hypertension].
Kasper Andersen1, Bertil Larsson2, Erik Björklund3
1med dr, överläkare, kardiologkliniken, Akademiska sjukhuset, Uppsala; institutionen för medicinska veten-skaper, Uppsala universitet, med dr, överläkare, kardiologkliniken; institutionen för medicinska veten-skaper, Uppsala universitet.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a lung condition often treated with surgery. Balloon pulmonary angioplasty (BPA) offers a safe alternative for patients ineligible for surgery, showing comparable outcomes.
Area of Science:
- Cardiology
- Pulmonary Medicine
- Interventional Cardiology
Background:
- Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious condition often following acute pulmonary embolism.
- Exertional dyspnea is the primary symptom experienced by CTEPH patients.
- Early assessment for pulmonary thromboendarterectomy (PEA) is crucial for CTEPH management.
Purpose of the Study:
- To evaluate balloon pulmonary angioplasty (BPA) as a treatment for CTEPH.
- To compare the safety and efficacy of BPA with existing surgical options.
- To determine the potential for subjective and objective improvements post-BPA treatment.
Main Methods:
- Review of treatment protocols for CTEPH patients.
- Analysis of outcomes for patients undergoing BPA.
- Comparison of BPA safety and efficacy against pulmonary thromboendarterectomy (PEA).
Main Results:
- Balloon pulmonary angioplasty (BPA) is a viable treatment option for CTEPH patients unsuitable for surgery.
- BPA requires multiple treatment sessions for optimal results.
- The safety profile of BPA is comparable to that of open surgical PEA.
Conclusions:
- BPA presents a safe and effective alternative for CTEPH management when PEA is not feasible.
- Further long-term studies are needed to fully establish the efficacy and safety of BPA.
- Patients undergoing BPA can expect subjective and objective clinical improvements.
More Related Videos
07:41Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
Published on: March 17, 2022
08:34Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...